var data={"title":"Hypercalcemia of malignancy: Mechanisms","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Hypercalcemia of malignancy: Mechanisms</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/hypercalcemia-of-malignancy-mechanisms/contributors\" class=\"contributor contributor_credentials\">Mara J Horwitz, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/hypercalcemia-of-malignancy-mechanisms/contributors\" class=\"contributor contributor_credentials\">Clifford J Rosen, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/hypercalcemia-of-malignancy-mechanisms/contributors\" class=\"contributor contributor_credentials\">Jean E Mulder, MD</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/hypercalcemia-of-malignancy-mechanisms/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Aug 22, 2016.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Hypercalcemia is relatively common in patients with cancer, occurring in approximately 20 to 30 percent of cases [<a href=\"https://www.uptodate.com/contents/hypercalcemia-of-malignancy-mechanisms/abstract/1\" class=\"abstract_t\">1</a>]. It is the most common cause of hypercalcemia in the inpatient setting. It occurs in patients with both solid tumors and hematologic malignancies. The most common cancers associated with hypercalcemia are breast and lung cancer and multiple myeloma. Malignancy is often evident clinically by the time it causes hypercalcemia, and patients with hypercalcemia of malignancy often have a poor prognosis. The mechanisms of hypercalcemia will be reviewed here. The clinical manifestations, diagnosis, and treatment of hypercalcemia are reviewed in detail separately. </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=clinical-manifestations-of-hypercalcemia\" class=\"medical medical_review\">&quot;Clinical manifestations of hypercalcemia&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=diagnostic-approach-to-hypercalcemia\" class=\"medical medical_review\">&quot;Diagnostic approach to hypercalcemia&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=treatment-of-hypercalcemia\" class=\"medical medical_review\">&quot;Treatment of hypercalcemia&quot;</a>.)</p><p/><p class=\"headingAnchor\" id=\"H2021818767\"><span class=\"h1\">MECHANISMS OF HYPERCALCEMIA</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>There are three major mechanisms by which hypercalcemia of malignancy can occur (<a href=\"image.htm?imageKey=ENDO%2F74189\" class=\"graphic graphic_table graphicRef74189 \">table 1</a>) [<a href=\"https://www.uptodate.com/contents/hypercalcemia-of-malignancy-mechanisms/abstract/1-3\" class=\"abstract_t\">1-3</a>]: </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Tumor secretion of parathyroid hormone-related protein (PTHrP)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Osteolytic metastases with local release of cytokines (including osteoclast activating factors)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Tumor production of 1,25-dihydroxyvitamin D (calcitriol)</p><p/><p>Ectopic tumoral secretion of parathyroid hormone (PTH) can also cause hypercalcemia, but it is rare.</p><p class=\"headingAnchor\" id=\"H1048261776\"><span class=\"h2\">PTH-related protein</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The most common cause of hypercalcemia in patients with nonmetastatic solid tumors and in some patients with non-Hodgkin lymphoma is secretion of PTHrP; this condition, also called humoral hypercalcemia of malignancy (HHM), accounts for up to 80 percent of patients with hypercalcemia of malignancy [<a href=\"https://www.uptodate.com/contents/hypercalcemia-of-malignancy-mechanisms/abstract/4-7\" class=\"abstract_t\">4-7</a>]. Patients with HHM most often have squamous cell carcinomas (lung, head, and neck) or renal, bladder, breast, or ovarian carcinomas (<a href=\"image.htm?imageKey=ENDO%2F74189\" class=\"graphic graphic_table graphicRef74189 \">table 1</a>). They typically have advanced disease and a poor prognosis [<a href=\"https://www.uptodate.com/contents/hypercalcemia-of-malignancy-mechanisms/abstract/8,9\" class=\"abstract_t\">8,9</a>].</p><p>PTHrP is a normal gene product expressed in a wide variety of neuroendocrine, epithelial, and mesoderm-derived tissues. Thus, in addition to patients with solid tumors, those with non-Hodgkin lymphoma [<a href=\"https://www.uptodate.com/contents/hypercalcemia-of-malignancy-mechanisms/abstract/4,5,10\" class=\"abstract_t\">4,5,10</a>], chronic myeloid leukemia (blast phase) [<a href=\"https://www.uptodate.com/contents/hypercalcemia-of-malignancy-mechanisms/abstract/11\" class=\"abstract_t\">11</a>], and adult T-cell leukemia-lymphoma may have PTHrP-induced hypercalcemia [<a href=\"https://www.uptodate.com/contents/hypercalcemia-of-malignancy-mechanisms/abstract/5,12,13\" class=\"abstract_t\">5,12,13</a>]. Tumor necrosis factor-beta also may contribute in some patients with adult T-cell leukemia-lymphoma [<a href=\"https://www.uptodate.com/contents/hypercalcemia-of-malignancy-mechanisms/abstract/14\" class=\"abstract_t\">14</a>]. (See <a href=\"topic.htm?path=clinical-manifestations-pathologic-features-and-diagnosis-of-adult-t-cell-leukemia-lymphoma#H3\" class=\"medical medical_review\">&quot;Clinical manifestations, pathologic features, and diagnosis of adult T cell leukemia-lymphoma&quot;, section on 'Pathogenesis'</a>.)</p><p>Purification of PTHrP has revealed some homology with PTH, particularly at the amino-terminal end, at which the first 13 amino acids are almost identical [<a href=\"https://www.uptodate.com/contents/hypercalcemia-of-malignancy-mechanisms/abstract/15\" class=\"abstract_t\">15</a>]. As a result of this close homology with PTH, PTHrP binds to the same PTH-1 receptor as does PTH and thus activates similar post-receptor pathways. This accounts for the ability of PTHrP to simulate some of the actions of PTH, including increases in bone resorption and distal tubular calcium reabsorption and inhibition of proximal tubular phosphate transport [<a href=\"https://www.uptodate.com/contents/hypercalcemia-of-malignancy-mechanisms/abstract/6,16-18\" class=\"abstract_t\">6,16-18</a>]. (See <a href=\"topic.htm?path=regulation-of-calcium-and-phosphate-balance\" class=\"medical medical_review\">&quot;Regulation of calcium and phosphate balance&quot;</a>.)</p><p>Structural divergence after the first 13 amino acids of the molecule accounts for its immunologic distinctiveness from PTH. PTHrP is less likely than PTH to stimulate 1,25-dihydroxyvitamin D production [<a href=\"https://www.uptodate.com/contents/hypercalcemia-of-malignancy-mechanisms/abstract/6,19-22\" class=\"abstract_t\">6,19-22</a>]. As a result, PTHrP does not increase intestinal calcium absorption. In patients with HHM, there is an uncoupling of bone resorption and formation, which results in a large flux of calcium from bone into the circulation. This, in combination with the reduced ability of the kidney to clear calcium, results in the striking hypercalcemia that occurs in HHM. Thus, hypercalcemia in HHM is due to the combined effects of PTHrP on kidney and bone [<a href=\"https://www.uptodate.com/contents/hypercalcemia-of-malignancy-mechanisms/abstract/6,16,23\" class=\"abstract_t\">6,16,23</a>].</p><p>Typical laboratory findings in patients with HHM include the following [<a href=\"https://www.uptodate.com/contents/hypercalcemia-of-malignancy-mechanisms/abstract/1,6,24\" class=\"abstract_t\">1,6,24</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Elevated serum PTHrP</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Very low or suppressed serum intact PTH (secretion of endogenous PTH is suppressed by PTHrP-mediated hypercalcemia)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Normal to low serum 1,25-dihydroxyvitamin D</p><p/><p>Serum PTHrP levels in patients with tumor-induced hypercalcemia can provide information regarding prognosis:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>It is a useful tumor marker for assessing the response to treatment of the tumor.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>It may predict the response to bisphosphonates. Serum PTHrP concentrations above 12 <span class=\"nowrap\">pmol/L</span> are frequently associated with both a smaller reduction in hypercalcemia and with recurrence of hypercalcemia within 14 days of therapy [<a href=\"https://www.uptodate.com/contents/hypercalcemia-of-malignancy-mechanisms/abstract/8,25,26\" class=\"abstract_t\">8,25,26</a>]. While the prognosis of cancer-associated hypercalcemia is generally poor, those who become normocalcemic with bisphosphonate therapy have a significantly better, although still short, survival (53 versus 19 days in one study) [<a href=\"https://www.uptodate.com/contents/hypercalcemia-of-malignancy-mechanisms/abstract/26\" class=\"abstract_t\">26</a>]. (See <a href=\"topic.htm?path=treatment-of-hypercalcemia#H6\" class=\"medical medical_review\">&quot;Treatment of hypercalcemia&quot;, section on 'Bisphosphonates'</a>.)</p><p/><p class=\"headingAnchor\" id=\"H2\"><span class=\"h2\">Osteolytic metastases</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Osteolytic metastases account for approximately 20 percent of cases of hypercalcemia of malignancy [<a href=\"https://www.uptodate.com/contents/hypercalcemia-of-malignancy-mechanisms/abstract/7\" class=\"abstract_t\">7</a>]. Induction of local osteolysis by tumor cells is common with some solid tumors that are metastatic to bone and with multiple myeloma, but it is less common with lymphoma and leukemia (<a href=\"image.htm?imageKey=ENDO%2F74189\" class=\"graphic graphic_table graphicRef74189 \">table 1</a>) [<a href=\"https://www.uptodate.com/contents/hypercalcemia-of-malignancy-mechanisms/abstract/1,3\" class=\"abstract_t\">1,3</a>]. The solid tumor that most often produces hypercalcemia by this mechanism is breast cancer. </p><p>The bone destruction observed in osteolytic metastases is primarily mediated by osteoclasts and is not a direct effect of tumor cells [<a href=\"https://www.uptodate.com/contents/hypercalcemia-of-malignancy-mechanisms/abstract/27\" class=\"abstract_t\">27</a>]. Instead, tumors produce many factors that stimulate osteoclast production and action locally, resulting in increased skeletal resorption and hypercalcemia. (See <a href=\"topic.htm?path=mechanisms-of-bone-metastases#H7\" class=\"medical medical_review\">&quot;Mechanisms of bone metastases&quot;, section on 'Osteolytic metastases'</a>.)</p><p>Typical findings in patients with osteolytic metastases include:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Low or suppressed serum intact PTH</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Low or low-normal serum 1,25-dihydroxyvitamin D</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Low or low-normal serum PTHrP (although tumor metastases in bone may secrete PTHrP locally, it is not usually measurable in a serum assay)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Extensive skeletal metastases or marrow infiltration</p><p/><p class=\"headingAnchor\" id=\"H3\"><span class=\"h3\">Breast cancer</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Breast cancer cells in bone express PTHrP more frequently than those in soft tissue sites or in the primary tumor. PTHrP produced by metastatic tumor cells in the bone microenvironment acts as a local (rather than systemic) factor to cause osteolysis [<a href=\"https://www.uptodate.com/contents/hypercalcemia-of-malignancy-mechanisms/abstract/24\" class=\"abstract_t\">24</a>]. This occurs in the absence of high serum PTHrP concentrations. However, in other patients with breast cancer, bone metastases, and hypercalcemia, serum PTHrP is elevated, suggesting a systemic effect as well [<a href=\"https://www.uptodate.com/contents/hypercalcemia-of-malignancy-mechanisms/abstract/28\" class=\"abstract_t\">28</a>]. (See <a href=\"#H1048261776\" class=\"local\">'PTH-related protein'</a> above.)</p><p>Locally produced PTHrP increases expression of receptor activator of nuclear factor kappa B ligand (RANKL) in bone. RANKL contributes to the development of hypercalcemia by binding to receptor activator of nuclear factor kappa B (RANK) on the surface of osteoclast precursors. The <span class=\"nowrap\">RANKL/RANK</span> interaction results in activation, migration, differentiation, and fusion of hematopoietic cells of the osteoclast lineage to begin the process of resorption. In addition, cytokines such as interleukin-6 (IL-6), IL-8, IL-1, and vascular endothelial growth factor (VEGF) are secreted by breast cancer cells and may contribute to the effects of PTHrP on bone resorption. (See <a href=\"topic.htm?path=mechanisms-of-bone-metastases#H15\" class=\"medical medical_review\">&quot;Mechanisms of bone metastases&quot;, section on 'Breast cancer'</a>.)</p><p>Among patients with breast cancer and extensive skeletal metastases, the administration of an antiestrogen (such as <a href=\"topic.htm?path=tamoxifen-drug-information\" class=\"drug drug_general\">tamoxifen</a>) can lead to hypercalcemia [<a href=\"https://www.uptodate.com/contents/hypercalcemia-of-malignancy-mechanisms/abstract/29,30\" class=\"abstract_t\">29,30</a>]. The presumed mechanism is release of bone resorbing factors from the tumor cells [<a href=\"https://www.uptodate.com/contents/hypercalcemia-of-malignancy-mechanisms/abstract/31\" class=\"abstract_t\">31</a>]. In addition, there has been a case report of flare hypercalcemia<strong> </strong>with an aromatase inhibitor [<a href=\"https://www.uptodate.com/contents/hypercalcemia-of-malignancy-mechanisms/abstract/32\" class=\"abstract_t\">32</a>].</p><p class=\"headingAnchor\" id=\"H4\"><span class=\"h3\">Multiple myeloma</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Hypercalcemia in multiple myeloma and in some cases of lymphoma where there is bone marrow infiltration by tumor has been ascribed to the release of osteoclast activating factors by the tumor cells [<a href=\"https://www.uptodate.com/contents/hypercalcemia-of-malignancy-mechanisms/abstract/33,34\" class=\"abstract_t\">33,34</a>]. Osteoclast-induced bone resorption may occur in discrete focal areas (lytic lesions) or throughout the skeleton. The high rate of bone resorption is associated with an absence of osteoblast-mediated bone formation, resulting in diffuse bone loss. The uncoupling of bone resorption and formation results from paracrine factors, which enhance osteoclast formation and activity and inhibit the capacity for marrow stromal cells to differentiate into osteoblasts [<a href=\"https://www.uptodate.com/contents/hypercalcemia-of-malignancy-mechanisms/abstract/33\" class=\"abstract_t\">33</a>]. In multiple myeloma, various studies have implicated IL-6, RANKL, macrophage inflammatory protein 1a, osteoprotegerin, and IL-3 as factors contributing to the development of lytic bone disease and hypercalcemia. (See <a href=\"topic.htm?path=mechanisms-of-bone-metastases#H8\" class=\"medical medical_review\">&quot;Mechanisms of bone metastases&quot;, section on 'Multiple myeloma'</a>.)</p><p class=\"headingAnchor\" id=\"H7\"><span class=\"h2\">1,25-dihydroxyvitamin D</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Increased production of 1,25-dihydroxyvitamin D (calcitriol) is the cause of almost all cases of hypercalcemia in Hodgkin lymphoma and approximately one-third of cases in non-Hodgkin lymphoma (<a href=\"image.htm?imageKey=ENDO%2F74189\" class=\"graphic graphic_table graphicRef74189 \">table 1</a>)&nbsp;[<a href=\"https://www.uptodate.com/contents/hypercalcemia-of-malignancy-mechanisms/abstract/10,35\" class=\"abstract_t\">10,35</a>]. An occasional patient with Hodgkin lymphoma, however, has hypercalcemia due to PTHrP, as do some with non-Hodgkin lymphoma, as stated above [<a href=\"https://www.uptodate.com/contents/hypercalcemia-of-malignancy-mechanisms/abstract/4,10,36\" class=\"abstract_t\">4,10,36</a>]. 1,25-dihydroxyvitamin D-induced hypercalcemia has also been described in patients with ovarian dysgerminoma [<a href=\"https://www.uptodate.com/contents/hypercalcemia-of-malignancy-mechanisms/abstract/37\" class=\"abstract_t\">37</a>] and lymphomatoid <span class=\"nowrap\">granulomatosis/angiocentric</span> lymphoma [<a href=\"https://www.uptodate.com/contents/hypercalcemia-of-malignancy-mechanisms/abstract/38\" class=\"abstract_t\">38</a>]; the latter finding is consistent with the frequent association of hypercalcemia with chronic granulomatous diseases, such as sarcoidosis and tuberculosis. (See <a href=\"topic.htm?path=hypercalcemia-in-granulomatous-diseases\" class=\"medical medical_review\">&quot;Hypercalcemia in granulomatous diseases&quot;</a>.)</p><p>In normal individuals, the conversion of 25-hydroxyvitamin D (calcidiol) to 1,25-dihydroxyvitamin D (calcitriol, the most active metabolite of vitamin D) occurs via a 1-hydroxylase in the kidney that is under the physiologic control of PTH and inhibited by high serum phosphate via fibroblast growth factor 23 (FGF-23) (see <a href=\"topic.htm?path=overview-of-vitamin-d#H1172644\" class=\"medical medical_review\">&quot;Overview of vitamin D&quot;, section on 'Metabolism'</a>). Hypercalcemia should suppress the release of PTH and therefore the production of 1,25-dihydroxyvitamin D. The lack of suppression of 1,25-dihydroxyvitamin D production in lymphoma is due to PTH-independent extrarenal production of 1,25-dihydroxyvitamin D from 25-hydroxyvitamin D by malignant lymphocytes, macrophages, or both.</p><p>Increased intestinal calcium absorption induced by high serum 1,25-dihydroxyvitamin D concentrations is the primary abnormality, although a 1,25-dihydroxyvitamin D-induced increase in bone resorption may play a contributory role. Patients with increased production of 1,25-dihydroxyvitamin D typically have low or suppressed serum intact PTH and elevated 1,25-dihydroxyvitamin D. In case reports, some patients have elevations of both 1,25-dihydroxyvitamin D and PTHrP [<a href=\"https://www.uptodate.com/contents/hypercalcemia-of-malignancy-mechanisms/abstract/39\" class=\"abstract_t\">39</a>]. Hypercalcemia induced by 1,25-dihydroxyvitamin D (but not PTHRP) usually responds to glucocorticoid therapy. (See <a href=\"topic.htm?path=treatment-of-hypercalcemia#H13\" class=\"medical medical_review\">&quot;Treatment of hypercalcemia&quot;, section on 'Glucocorticoids'</a>.)</p><p class=\"headingAnchor\" id=\"H8\"><span class=\"h2\">Ectopic PTH secretion</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>A few patients with ectopic secretion of PTH have been described; among the tumors were an ovarian carcinoma, small cell and squamous cell lung carcinomas, a primitive neuroectodermal tumor, thyroid papillary carcinoma, metastatic rhabdomyosarcoma, and pancreatic malignancy (<a href=\"image.htm?imageKey=ENDO%2F74189\" class=\"graphic graphic_table graphicRef74189 \">table 1</a>) [<a href=\"https://www.uptodate.com/contents/hypercalcemia-of-malignancy-mechanisms/abstract/40-47\" class=\"abstract_t\">40-47</a>]. In these case reports, serum intact PTH was elevated, and some patients were diagnosed after neck exploration failed to identify a parathyroid adenoma. </p><p class=\"headingAnchor\" id=\"H9\"><span class=\"h1\">COEXISTING PRIMARY HYPERPARATHYROIDISM</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>There is a higher incidence of cancer in patients with primary hyperparathyroidism and of primary hyperparathyroidism in patients with cancer [<a href=\"https://www.uptodate.com/contents/hypercalcemia-of-malignancy-mechanisms/abstract/48,49\" class=\"abstract_t\">48,49</a>]. Thus, serum parathyroid hormone (PTH) should be measured in hypercalcemic patients with cancer [<a href=\"https://www.uptodate.com/contents/hypercalcemia-of-malignancy-mechanisms/abstract/50\" class=\"abstract_t\">50</a>]. If serum parathyroid hormone-related protein (PTHrP) and PTH concentrations are both high, then coexisting primary hyperparathyroidism is probably present as well. </p><p>Mild hypercalcemia due to primary hyperparathyroidism often precedes the acute and more severe hypercalcemia that is seen with hypercalcemia of malignancy. If serum PTH is elevated and PTHrP is not elevated, then primary hyperparathyroidism is probably the sole cause for the hypercalcemia [<a href=\"https://www.uptodate.com/contents/hypercalcemia-of-malignancy-mechanisms/abstract/4\" class=\"abstract_t\">4</a>]. (See <a href=\"topic.htm?path=primary-hyperparathyroidism-diagnosis-differential-diagnosis-and-evaluation\" class=\"medical medical_review\">&quot;Primary hyperparathyroidism: Diagnosis, differential diagnosis, and evaluation&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H4288754659\"><span class=\"h1\">DETERMINING THE MECHANISM</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Most patients with hypercalcemia of malignancy have clinical evidence of malignancy at the time of hypercalcemia diagnosis. Humoral hypercalcemia is likely the cause of hypercalcemia in any patient with a solid tumor in the absence of bony metastases. Local release of cytokines from osteolytic metastases is the likely cause of hypercalcemia in patients with extensive skeletal metastases or marrow infiltration. Hypercalcemia induced by 1,25-dihydroxyvitamin D should be suspected in patients with lymphoma. </p><p>Hypercalcemia of malignancy should also be suspected in patients with otherwise unexplained hypercalcemia and a low serum PTH concentration. (See <a href=\"topic.htm?path=etiology-of-hypercalcemia\" class=\"medical medical_review\">&quot;Etiology of hypercalcemia&quot;</a>.)</p><p>The approach to determining the mechanism of hypercalcemia is reviewed briefly below and in more detail separately (<a href=\"image.htm?imageKey=ENDO%2F51698\" class=\"graphic graphic_algorithm graphicRef51698 \">algorithm 1</a>) (see <a href=\"topic.htm?path=diagnostic-approach-to-hypercalcemia\" class=\"medical medical_review\">&quot;Diagnostic approach to hypercalcemia&quot;</a>):</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Once hypercalcemia is confirmed, we measure serum PTH. An elevated or mid- to upper-normal value generally indicates primary hyperparathyroidism.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In the presence of low-normal or low serum PTH concentrations (eg, &lt;20 <span class=\"nowrap\">pg/mL),</span> PTHrP and vitamin D metabolites should be measured to assess for hypercalcemia of malignancy and vitamin D intoxication.</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Elevated PTHrP is consistent with humoral hypercalcemia of malignancy.</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Increased levels of 1,25-dihydroxyvitamin D may be induced by direct intake of this metabolite, extrarenal production in granulomatous diseases or lymphoma, or increased renal production that can be induced by primary hyperparathyroidism or ectopic PTH secretion but not by PTHrP. </p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Markedly elevated 25-hydroxyvitamin D is consistent with vitamin D intoxication. Although the serum concentration of 25(OH)D at which hypercalcemia typically occurs is undefined, many experts define vitamin D intoxication as a value &gt;150 <span class=\"nowrap\">ng/mL</span> (374 <span class=\"nowrap\">nmol/L)</span> [<a href=\"https://www.uptodate.com/contents/hypercalcemia-of-malignancy-mechanisms/abstract/51\" class=\"abstract_t\">51</a>]. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>If PTHrP and vitamin D metabolites are not elevated, another source for the hypercalcemia must be considered. Additional laboratory data (including serum and urine protein electrophoresis and serum free light chain assay for possible multiple myeloma, thyroid-stimulating hormone [TSH], and vitamin A) will often lead to the correct diagnosis. Some patients may require imaging (eg, skeletal radiographs) for diagnosis of osteolytic metastases if the diagnosis is not clear from history. (See <a href=\"topic.htm?path=diagnostic-approach-to-hypercalcemia#H8\" class=\"medical medical_review\">&quot;Diagnostic approach to hypercalcemia&quot;, section on 'Other tests'</a>.)</p><p/><p class=\"headingAnchor\" id=\"H3828770985\"><span class=\"h1\">TREATMENT</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The treatment of hypercalcemia is reviewed separately. (See <a href=\"topic.htm?path=treatment-of-hypercalcemia#H1248397\" class=\"medical medical_review\">&quot;Treatment of hypercalcemia&quot;, section on 'Preferred approach'</a>.)</p><p class=\"headingAnchor\" id=\"H10\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Hypercalcemia is not uncommon in patients with malignancy, and it is associated with a poor prognosis. The most common tumors that cause hypercalcemia are breast cancer, multiple myeloma, lymphoma, and squamous cell cancers (<a href=\"image.htm?imageKey=ENDO%2F74189\" class=\"graphic graphic_table graphicRef74189 \">table 1</a>). (See <a href=\"#H1\" class=\"local\">'Introduction'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>There are three major mechanisms by which hypercalcemia of malignancy can occur:</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Tumor secretion of parathyroid hormone-related protein (PTHrP) (see <a href=\"#H1048261776\" class=\"local\">'PTH-related protein'</a> above)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Osteolytic metastases with local release of cytokines (see <a href=\"#H2\" class=\"local\">'Osteolytic metastases'</a> above)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Tumor production of 1,25-dihydroxyvitamin D (see <a href=\"#H7\" class=\"local\">'1,25-dihydroxyvitamin D'</a> above)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Hypercalcemia in patients with tumors secreting PTHrP is due to both increased bone resorption and distal renal tubular calcium reabsorption, whereas hypercalcemia in patients with osteolytic metastases is primarily due to increased bone resorption and release of calcium from bone. In patients with tumoral production of 1,25-dihydroxyvitamin D, hypercalcemia is the result of a combination of increased intestinal calcium absorption and bone resorption. (See <a href=\"#H2021818767\" class=\"local\">'Mechanisms of hypercalcemia'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The initial approach to determining the mechanism of hypercalcemia in the presence of a low-normal or low serum parathyroid hormone (PTH) concentration (&lt;20 <span class=\"nowrap\">pg/mL)</span> includes measurement of PTHrP and vitamin D metabolites (<a href=\"image.htm?imageKey=ENDO%2F51698\" class=\"graphic graphic_algorithm graphicRef51698 \">algorithm 1</a>). (See <a href=\"#H4288754659\" class=\"local\">'Determining the mechanism'</a> above and <a href=\"topic.htm?path=diagnostic-approach-to-hypercalcemia\" class=\"medical medical_review\">&quot;Diagnostic approach to hypercalcemia&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>If PTHrP and vitamin D metabolites are not elevated, another source for the hypercalcemia must be considered. Additional laboratory data (including serum and urine protein electrophoresis and serum free light chain assay for possible multiple myeloma, thyroid-stimulating hormone [TSH], and vitamin A) will often lead to the correct diagnosis. (See <a href=\"#H4288754659\" class=\"local\">'Determining the mechanism'</a> above and <a href=\"topic.htm?path=diagnostic-approach-to-hypercalcemia#H8\" class=\"medical medical_review\">&quot;Diagnostic approach to hypercalcemia&quot;, section on 'Other tests'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The treatment of hypercalcemia of malignancy is reviewed separately. (See <a href=\"topic.htm?path=treatment-of-hypercalcemia\" class=\"medical medical_review\">&quot;Treatment of hypercalcemia&quot;</a>.)</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/hypercalcemia-of-malignancy-mechanisms/abstract/1\" class=\"nounderline abstract_t\">Stewart AF. Clinical practice. Hypercalcemia associated with cancer. N Engl J Med 2005; 352:373.</a></li><li><a href=\"https://www.uptodate.com/contents/hypercalcemia-of-malignancy-mechanisms/abstract/2\" class=\"nounderline abstract_t\">Clines GA, Guise TA. Hypercalcaemia of malignancy and basic research on mechanisms responsible for osteolytic and osteoblastic metastasis to bone. Endocr Relat Cancer 2005; 12:549.</a></li><li><a href=\"https://www.uptodate.com/contents/hypercalcemia-of-malignancy-mechanisms/abstract/3\" class=\"nounderline abstract_t\">Mirrakhimov AE. Hypercalcemia of Malignancy: An Update on Pathogenesis and Management. N Am J Med Sci 2015; 7:483.</a></li><li><a href=\"https://www.uptodate.com/contents/hypercalcemia-of-malignancy-mechanisms/abstract/4\" class=\"nounderline abstract_t\">Ratcliffe WA, Hutchesson AC, Bundred NJ, Ratcliffe JG. Role of assays for parathyroid-hormone-related protein in investigation of hypercalcaemia. Lancet 1992; 339:164.</a></li><li><a href=\"https://www.uptodate.com/contents/hypercalcemia-of-malignancy-mechanisms/abstract/5\" class=\"nounderline abstract_t\">Ikeda K, Ohno H, Hane M, et al. Development of a sensitive two-site immunoradiometric assay for parathyroid hormone-related peptide: evidence for elevated levels in plasma from patients with adult T-cell leukemia/lymphoma and B-cell lymphoma. J Clin Endocrinol Metab 1994; 79:1322.</a></li><li><a href=\"https://www.uptodate.com/contents/hypercalcemia-of-malignancy-mechanisms/abstract/6\" class=\"nounderline abstract_t\">Horwitz MJ, Tedesco MB, Sereika SM, et al. Direct comparison of sustained infusion of human parathyroid hormone-related protein-(1-36) [hPTHrP-(1-36)] versus hPTH-(1-34) on serum calcium, plasma 1,25-dihydroxyvitamin D concentrations, and fractional calcium excretion in healthy human volunteers. J Clin Endocrinol Metab 2003; 88:1603.</a></li><li class=\"breakAll\">Horwitz MJ et al. Non-Parathryoid Hypercalcemia. In: Primer on the metabolic bone diseases and disorders of mineral metabolism, 8th ed, Rosen CJ (ed), Wiley &ndash;Blackwell and The American Society for Bone and Mineral Research. 2013. 562.</li><li><a href=\"https://www.uptodate.com/contents/hypercalcemia-of-malignancy-mechanisms/abstract/8\" class=\"nounderline abstract_t\">Wimalawansa SJ. Significance of plasma PTH-rp in patients with hypercalcemia of malignancy treated with bisphosphonate. Cancer 1994; 73:2223.</a></li><li><a href=\"https://www.uptodate.com/contents/hypercalcemia-of-malignancy-mechanisms/abstract/9\" class=\"nounderline abstract_t\">Pecherstorfer M, Schilling T, Blind E, et al. Parathyroid hormone-related protein and life expectancy in hypercalcemic cancer patients. J Clin Endocrinol Metab 1994; 78:1268.</a></li><li><a href=\"https://www.uptodate.com/contents/hypercalcemia-of-malignancy-mechanisms/abstract/10\" class=\"nounderline abstract_t\">Roodman GD. Mechanisms of bone lesions in multiple myeloma and lymphoma. Cancer 1997; 80:1557.</a></li><li><a href=\"https://www.uptodate.com/contents/hypercalcemia-of-malignancy-mechanisms/abstract/11\" class=\"nounderline abstract_t\">Seymour JF, Grill V, Martin TJ, et al. Hypercalcemia in the blastic phase of chronic myeloid leukemia associated with elevated parathyroid hormone-related protein. Leukemia 1993; 7:1672.</a></li><li><a href=\"https://www.uptodate.com/contents/hypercalcemia-of-malignancy-mechanisms/abstract/12\" class=\"nounderline abstract_t\">Nakamura Y, Bando H, Shintani Y, et al. Serum parathyroid hormone-related protein concentrations in patients with hematologic malignancies or solid tumors. Acta Endocrinol (Copenh) 1992; 127:324.</a></li><li><a href=\"https://www.uptodate.com/contents/hypercalcemia-of-malignancy-mechanisms/abstract/13\" class=\"nounderline abstract_t\">Inoue D, Matsumoto T, Ogata E, Ikeda K. 22-Oxacalcitriol, a noncalcemic analogue of calcitriol, suppresses both cell proliferation and parathyroid hormone-related peptide gene expression in human T cell lymphotrophic virus, type I-infected T cells. J Biol Chem 1993; 268:16730.</a></li><li><a href=\"https://www.uptodate.com/contents/hypercalcemia-of-malignancy-mechanisms/abstract/14\" class=\"nounderline abstract_t\">Ishibashi K, Ishitsuka K, Chuman Y, et al. Tumor necrosis factor-beta in the serum of adult T-cell leukemia with hypercalcemia. Blood 1991; 77:2451.</a></li><li><a href=\"https://www.uptodate.com/contents/hypercalcemia-of-malignancy-mechanisms/abstract/15\" class=\"nounderline abstract_t\">Burtis WJ, Brady TG, Orloff JJ, et al. Immunochemical characterization of circulating parathyroid hormone-related protein in patients with humoral hypercalcemia of cancer. N Engl J Med 1990; 322:1106.</a></li><li><a href=\"https://www.uptodate.com/contents/hypercalcemia-of-malignancy-mechanisms/abstract/16\" class=\"nounderline abstract_t\">Rizzoli R, Ferrari SL, Pizurki L, et al. Actions of parathyroid hormone and parathyroid hormone-related protein. J Endocrinol Invest 1992; 15:51.</a></li><li><a href=\"https://www.uptodate.com/contents/hypercalcemia-of-malignancy-mechanisms/abstract/17\" class=\"nounderline abstract_t\">Fraher LJ, Hodsman AB, Jonas K, et al. A comparison of the in vivo biochemical responses to exogenous parathyroid hormone-(1-34) [PTH-(1-34)] and PTH-related peptide-(1-34) in man. J Clin Endocrinol Metab 1992; 75:417.</a></li><li><a href=\"https://www.uptodate.com/contents/hypercalcemia-of-malignancy-mechanisms/abstract/18\" class=\"nounderline abstract_t\">Esbrit P, Egido J. The emerging role of parathyroid hormone-related protein as a renal regulating factor. Nephrol Dial Transplant 2000; 15:1109.</a></li><li><a href=\"https://www.uptodate.com/contents/hypercalcemia-of-malignancy-mechanisms/abstract/19\" class=\"nounderline abstract_t\">Schilling T, Pecherstorfer M, Blind E, et al. Parathyroid hormone-related protein (PTHrP) does not regulate 1,25-dihydroxyvitamin D serum levels in hypercalcemia of malignancy. J Clin Endocrinol Metab 1993; 76:801.</a></li><li><a href=\"https://www.uptodate.com/contents/hypercalcemia-of-malignancy-mechanisms/abstract/20\" class=\"nounderline abstract_t\">Schweitzer DH, Hamdy NA, Fr&ouml;lich M, et al. Malignancy-associated hypercalcaemia: resolution of controversies over vitamin D metabolism by a pathophysiological approach to the syndrome. Clin Endocrinol (Oxf) 1994; 41:251.</a></li><li><a href=\"https://www.uptodate.com/contents/hypercalcemia-of-malignancy-mechanisms/abstract/21\" class=\"nounderline abstract_t\">Nakayama K, Fukumoto S, Takeda S, et al. Differences in bone and vitamin D metabolism between primary hyperparathyroidism and malignancy-associated hypercalcemia. J Clin Endocrinol Metab 1996; 81:607.</a></li><li><a href=\"https://www.uptodate.com/contents/hypercalcemia-of-malignancy-mechanisms/abstract/22\" class=\"nounderline abstract_t\">Horwitz MJ, Tedesco MB, Sereika SM, et al. Continuous PTH and PTHrP infusion causes suppression of bone formation and discordant effects on 1,25(OH)2 vitamin D. J Bone Miner Res 2005; 20:1792.</a></li><li><a href=\"https://www.uptodate.com/contents/hypercalcemia-of-malignancy-mechanisms/abstract/23\" class=\"nounderline abstract_t\">Syed MA, Horwitz MJ, Tedesco MB, et al. Parathyroid hormone-related protein-(1--36) stimulates renal tubular calcium reabsorption in normal human volunteers: implications for the pathogenesis of humoral hypercalcemia of malignancy. J Clin Endocrinol Metab 2001; 86:1525.</a></li><li><a href=\"https://www.uptodate.com/contents/hypercalcemia-of-malignancy-mechanisms/abstract/24\" class=\"nounderline abstract_t\">Mundy GR, Edwards JR. PTH-related peptide (PTHrP) in hypercalcemia. J Am Soc Nephrol 2008; 19:672.</a></li><li><a href=\"https://www.uptodate.com/contents/hypercalcemia-of-malignancy-mechanisms/abstract/25\" class=\"nounderline abstract_t\">Gurney H, Grill V, Martin TJ. Parathyroid hormone-related protein and response to pamidronate in tumour-induced hypercalcaemia. Lancet 1993; 341:1611.</a></li><li><a href=\"https://www.uptodate.com/contents/hypercalcemia-of-malignancy-mechanisms/abstract/26\" class=\"nounderline abstract_t\">Ling PJ, A'Hern RP, Hardy JR. Analysis of survival following treatment of tumour-induced hypercalcaemia with intravenous pamidronate (APD). Br J Cancer 1995; 72:206.</a></li><li><a href=\"https://www.uptodate.com/contents/hypercalcemia-of-malignancy-mechanisms/abstract/27\" class=\"nounderline abstract_t\">Quinn JM, Matsumura Y, Tarin D, et al. Cellular and hormonal mechanisms associated with malignant bone resorption. Lab Invest 1994; 71:465.</a></li><li><a href=\"https://www.uptodate.com/contents/hypercalcemia-of-malignancy-mechanisms/abstract/28\" class=\"nounderline abstract_t\">Grill V, Ho P, Body JJ, et al. Parathyroid hormone-related protein: elevated levels in both humoral hypercalcemia of malignancy and hypercalcemia complicating metastatic breast cancer. J Clin Endocrinol Metab 1991; 73:1309.</a></li><li><a href=\"https://www.uptodate.com/contents/hypercalcemia-of-malignancy-mechanisms/abstract/29\" class=\"nounderline abstract_t\">Legha SS, Powell K, Buzdar AU, Blumenschein GR. Tamoxifen-induced hypercalcemia in breast cancer. Cancer 1981; 47:2803.</a></li><li><a href=\"https://www.uptodate.com/contents/hypercalcemia-of-malignancy-mechanisms/abstract/30\" class=\"nounderline abstract_t\">Arumugam GP, Sundravel S, Shanthi P, Sachdanandam P. Tamoxifen flare hypercalcemia: an additional support for gallium nitrate usage. J Bone Miner Metab 2006; 24:243.</a></li><li><a href=\"https://www.uptodate.com/contents/hypercalcemia-of-malignancy-mechanisms/abstract/31\" class=\"nounderline abstract_t\">Valentin-Opran A, Eilon G, Saez S, Mundy GR. Estrogens and antiestrogens stimulate release of bone resorbing activity by cultured human breast cancer cells. J Clin Invest 1985; 75:726.</a></li><li><a href=\"https://www.uptodate.com/contents/hypercalcemia-of-malignancy-mechanisms/abstract/32\" class=\"nounderline abstract_t\">Kuroi K, Yamashita T, Aruga T, et al. Flare hypercalcemia after letrozole in a patient with liver metastasis from breast cancer: a case report. J Med Case Rep 2011; 5:495.</a></li><li><a href=\"https://www.uptodate.com/contents/hypercalcemia-of-malignancy-mechanisms/abstract/33\" class=\"nounderline abstract_t\">Roodman GD. Pathogenesis of myeloma bone disease. J Cell Biochem 2010; 109:283.</a></li><li class=\"breakAll\">Silbermann R and Roodman GD. Hematologic malignancies and Bone. In: Primer on the metabolic bone diseases and disorders of mineral metabolism, 8th ed, Rosen CJ (ed), Wiley-Blackwell and The American Society for Bone and Mineral Research, Washington, DC. 2013. 694.</li><li><a href=\"https://www.uptodate.com/contents/hypercalcemia-of-malignancy-mechanisms/abstract/35\" class=\"nounderline abstract_t\">Seymour JF, Gagel RF. Calcitriol: the major humoral mediator of hypercalcemia in Hodgkin's disease and non-Hodgkin's lymphomas. Blood 1993; 82:1383.</a></li><li><a href=\"https://www.uptodate.com/contents/hypercalcemia-of-malignancy-mechanisms/abstract/36\" class=\"nounderline abstract_t\">Henderson JE, Shustik C, Kremer R, et al. Circulating concentrations of parathyroid hormone-like peptide in malignancy and in hyperparathyroidism. J Bone Miner Res 1990; 5:105.</a></li><li><a href=\"https://www.uptodate.com/contents/hypercalcemia-of-malignancy-mechanisms/abstract/37\" class=\"nounderline abstract_t\">Hibi M, Hara F, Tomishige H, et al. 1,25-dihydroxyvitamin D-mediated hypercalcemia in ovarian dysgerminoma. Pediatr Hematol Oncol 2008; 25:73.</a></li><li><a href=\"https://www.uptodate.com/contents/hypercalcemia-of-malignancy-mechanisms/abstract/38\" class=\"nounderline abstract_t\">Scheinman SJ, Kelberman MW, Tatum AH, Zamkoff KW. Hypercalcemia with excess serum 1,25 dihydroxyvitamin D in lymphomatoid granulomatosis/angiocentric lymphoma. Am J Med Sci 1991; 301:178.</a></li><li><a href=\"https://www.uptodate.com/contents/hypercalcemia-of-malignancy-mechanisms/abstract/39\" class=\"nounderline abstract_t\">Shivnani SB, Shelton JM, Richardson JA, Maalouf NM. Hypercalcemia of malignancy with simultaneous elevation in serum parathyroid hormone--related peptide and 1,25-dihydroxyvitamin D in a patient with metastatic renal cell carcinoma. Endocr Pract 2009; 15:234.</a></li><li><a href=\"https://www.uptodate.com/contents/hypercalcemia-of-malignancy-mechanisms/abstract/40\" class=\"nounderline abstract_t\">Yoshimoto K, Yamasaki R, Sakai H, et al. Ectopic production of parathyroid hormone by small cell lung cancer in a patient with hypercalcemia. J Clin Endocrinol Metab 1989; 68:976.</a></li><li><a href=\"https://www.uptodate.com/contents/hypercalcemia-of-malignancy-mechanisms/abstract/41\" class=\"nounderline abstract_t\">Nussbaum SR, Gaz RD, Arnold A. Hypercalcemia and ectopic secretion of parathyroid hormone by an ovarian carcinoma with rearrangement of the gene for parathyroid hormone. N Engl J Med 1990; 323:1324.</a></li><li><a href=\"https://www.uptodate.com/contents/hypercalcemia-of-malignancy-mechanisms/abstract/42\" class=\"nounderline abstract_t\">Strewler GJ, Budayr AA, Clark OH, Nissenson RA. Production of parathyroid hormone by a malignant nonparathyroid tumor in a hypercalcemic patient. J Clin Endocrinol Metab 1993; 76:1373.</a></li><li><a href=\"https://www.uptodate.com/contents/hypercalcemia-of-malignancy-mechanisms/abstract/43\" class=\"nounderline abstract_t\">Nielsen PK, Rasmussen AK, Feldt-Rasmussen U, et al. Ectopic production of intact parathyroid hormone by a squamous cell lung carcinoma in vivo and in vitro. J Clin Endocrinol Metab 1996; 81:3793.</a></li><li><a href=\"https://www.uptodate.com/contents/hypercalcemia-of-malignancy-mechanisms/abstract/44\" class=\"nounderline abstract_t\">Wong K, Tsuda S, Mukai R, et al. Parathyroid hormone expression in a patient with metastatic nasopharyngeal rhabdomyosarcoma and hypercalcemia. Endocrine 2005; 27:83.</a></li><li><a href=\"https://www.uptodate.com/contents/hypercalcemia-of-malignancy-mechanisms/abstract/45\" class=\"nounderline abstract_t\">VanHouten JN, Yu N, Rimm D, et al. Hypercalcemia of malignancy due to ectopic transactivation of the parathyroid hormone gene. J Clin Endocrinol Metab 2006; 91:580.</a></li><li><a href=\"https://www.uptodate.com/contents/hypercalcemia-of-malignancy-mechanisms/abstract/46\" class=\"nounderline abstract_t\">Vacher-Coponat H, Opris A, Denizot A, et al. Hypercalcaemia induced by excessive parathyroid hormone secretion in a patient with a neuroendocrine tumour. Nephrol Dial Transplant 2005; 20:2832.</a></li><li><a href=\"https://www.uptodate.com/contents/hypercalcemia-of-malignancy-mechanisms/abstract/47\" class=\"nounderline abstract_t\">Kandil E, Noureldine S, Khalek MA, et al. Ectopic secretion of parathyroid hormone in a neuroendocrine tumor: a case report and review of the literature. Int J Clin Exp Med 2011; 4:234.</a></li><li><a href=\"https://www.uptodate.com/contents/hypercalcemia-of-malignancy-mechanisms/abstract/48\" class=\"nounderline abstract_t\">Hutchesson AC, Bundred NJ, Ratcliffe WA. Survival in hypercalcaemic patients with cancer and co-existing primary hyperparathyroidism. Postgrad Med J 1995; 71:28.</a></li><li><a href=\"https://www.uptodate.com/contents/hypercalcemia-of-malignancy-mechanisms/abstract/49\" class=\"nounderline abstract_t\">Strodel WE, Thompson NW, Eckhauser FE, Knol JA. Malignancy and concomitant primary hyperparathyroidism. J Surg Oncol 1988; 37:10.</a></li><li><a href=\"https://www.uptodate.com/contents/hypercalcemia-of-malignancy-mechanisms/abstract/50\" class=\"nounderline abstract_t\">Casez J, Pfammatter R, Nguyen Q, et al. Diagnostic approach to hypercalcemia: relevance of parathyroid hormone and parathyroid hormone-related protein measurements. Eur J Intern Med 2001; 12:344.</a></li><li><a href=\"https://www.uptodate.com/contents/hypercalcemia-of-malignancy-mechanisms/abstract/51\" class=\"nounderline abstract_t\">Holick MF. Vitamin D deficiency. N Engl J Med 2007; 357:266.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 842 Version 12.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H10\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H2021818767\" id=\"outline-link-H2021818767\">MECHANISMS OF HYPERCALCEMIA</a><ul><li><a href=\"#H1048261776\" id=\"outline-link-H1048261776\">PTH-related protein</a></li><li><a href=\"#H2\" id=\"outline-link-H2\">Osteolytic metastases</a><ul><li><a href=\"#H3\" id=\"outline-link-H3\">- Breast cancer</a></li><li><a href=\"#H4\" id=\"outline-link-H4\">- Multiple myeloma</a></li></ul></li><li><a href=\"#H7\" id=\"outline-link-H7\">1,25-dihydroxyvitamin D</a></li><li><a href=\"#H8\" id=\"outline-link-H8\">Ectopic PTH secretion</a></li></ul></li><li><a href=\"#H9\" id=\"outline-link-H9\">COEXISTING PRIMARY HYPERPARATHYROIDISM</a></li><li><a href=\"#H4288754659\" id=\"outline-link-H4288754659\">DETERMINING THE MECHANISM</a></li><li><a href=\"#H3828770985\" id=\"outline-link-H3828770985\">TREATMENT</a></li><li><a href=\"#H10\" id=\"outline-link-H10\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"ENDO/842|ALG\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"ALGORITHMS\">ALGORITHMS</a></div><ul><li><a href=\"image.htm?imageKey=ENDO/51698\" class=\"graphic graphic_algorithm\">- Diagnostic approach to hypercalcemia</a></li></ul></li><li><div id=\"ENDO/842|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=ENDO/74189\" class=\"graphic graphic_table\">- Cancers associated with hypercalcemia</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-of-hypercalcemia\" class=\"medical medical_review\">Clinical manifestations of hypercalcemia</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-pathologic-features-and-diagnosis-of-adult-t-cell-leukemia-lymphoma\" class=\"medical medical_review\">Clinical manifestations, pathologic features, and diagnosis of adult T cell leukemia-lymphoma</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=diagnostic-approach-to-hypercalcemia\" class=\"medical medical_review\">Diagnostic approach to hypercalcemia</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=etiology-of-hypercalcemia\" class=\"medical medical_review\">Etiology of hypercalcemia</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=hypercalcemia-in-granulomatous-diseases\" class=\"medical medical_review\">Hypercalcemia in granulomatous diseases</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=mechanisms-of-bone-metastases\" class=\"medical medical_review\">Mechanisms of bone metastases</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-vitamin-d\" class=\"medical medical_review\">Overview of vitamin D</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=primary-hyperparathyroidism-diagnosis-differential-diagnosis-and-evaluation\" class=\"medical medical_review\">Primary hyperparathyroidism: Diagnosis, differential diagnosis, and evaluation</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=regulation-of-calcium-and-phosphate-balance\" class=\"medical medical_review\">Regulation of calcium and phosphate balance</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-hypercalcemia\" class=\"medical medical_review\">Treatment of hypercalcemia</a></li></ul></div></div>","javascript":null}